Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Melanoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 13Specimen Handling 12pembrolizumab 11Magnetic Resonance Spectroscopy 10Biopsy 10Cyclophosphamide 9X-Rays 7Ifosfamide 7Radiotherapy 6Phantoms, Imaging 6Gemcitabine 6liposomal doxorubicin 5Nivolumab 5tazemetostat 4palbociclib 4fludarabine 4atezolizumab 4Temozolomide 4Radiation 4Nuclear Medicine Department, Hospital 4Irinotecan 4larotrectinib 3cabozantinib 3Surveys and Questionnaires 3Ipilimumab 3Carboplatin 3Bevacizumab 3ulixertinib 2tipifarnib 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Vaccines × 90 days × Clear all
NCT05264974 2026-05-27

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

University of Florida

Phase 1 Suspended
18 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡